Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1987 Jun;23(6):759–763. doi: 10.1111/j.1365-2125.1987.tb03112.x

Lack of influence of cigarette smoking on triazolam pharmacokinetics.

H R Ochs, D J Greenblatt, E S Burstein
PMCID: PMC1386172  PMID: 3606935

Abstract

The influence of cigarette smoking on the pharmacokinetics of a single dose of the triazolobenzodiazepine hypnotic triazolam was evaluated in 12 healthy nonsmoking male volunteers and in 12 male subjects, matched for age, height and weight, who smoked an average of 24 cigarettes a day (range: 15-30). Triazolam kinetics were determined from multiple serum concentrations measured during 15 h after a single 0.5 mg dose. There were no significant differences between nonsmoking controls and cigarette smokers in the peak serum triazolam concentration (4.64 vs 4.73 ng ml-1), the time of peak concentration (0.98 vs 1.0 h after dosage), elimination half-life (2.8 vs 2.5 h), or oral clearance of triazolam (506 vs 627 ml min-1). Likewise there were no significant differences between groups in the extent of triazolam binding to serum protein (18.8 vs 18.5% unbound). Altered pharmacodynamics of triazolam in cigarette smokers are not likely to be explained by altered pharmacokinetics.

Full text

PDF
759

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Dawson G. W., Vestal R. E. Smoking and drug metabolism. Pharmacol Ther. 1981;15(2):207–221. doi: 10.1016/0163-7258(81)90042-5. [DOI] [PubMed] [Google Scholar]
  2. Eberts F. S., Jr, Philopoulos Y., Reineke L. M., Vliek R. W. Triazolam disposition. Clin Pharmacol Ther. 1981 Jan;29(1):81–93. doi: 10.1038/clpt.1981.14. [DOI] [PubMed] [Google Scholar]
  3. Greenblatt D. J., Divoll M., Abernethy D. R., Moschitto L. J., Smith R. B., Shader R. I. Reduced clearance of triazolam in old age: relation to antipyrine oxidizing capacity. Br J Clin Pharmacol. 1983 Mar;15(3):303–309. doi: 10.1111/j.1365-2125.1983.tb01503.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Greenblatt D. J., Divoll M., Moschitto L. J., Shader R. I. Electron-capture gas chromatographic analysis of the triazolobenzodiazepines alprazolam and triazolam. J Chromatogr. 1981 Sep 11;225(1):202–207. doi: 10.1016/s0378-4347(00)80261-3. [DOI] [PubMed] [Google Scholar]
  5. Hughes J. R., Hatsukami D. K., Mitchell J. E., Dahlgren L. A. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry. 1986 Aug;143(8):993–997. doi: 10.1176/ajp.143.8.993. [DOI] [PubMed] [Google Scholar]
  6. Jusko W. J. Influence of cigarette smoking on drug metabolism in man. Drug Metab Rev. 1979;9(2):221–236. doi: 10.3109/03602537908993892. [DOI] [PubMed] [Google Scholar]
  7. Jusko W. J. Role of tobacco smoking in pharmacokinetics. J Pharmacokinet Biopharm. 1978 Feb;6(1):7–39. doi: 10.1007/BF01066061. [DOI] [PubMed] [Google Scholar]
  8. Moschitto L. J., Greenblatt D. J. Concentration-independent plasma protein binding of benzodiazepines. J Pharm Pharmacol. 1983 Mar;35(3):179–180. doi: 10.1111/j.2042-7158.1983.tb04302.x. [DOI] [PubMed] [Google Scholar]
  9. Norman T. R., Fulton A., Burrows G. D., Maguire K. P. Pharmacokinetics of N-desmethyldiazepam after a single oral dose of clorazepate: the effect of smoking. Eur J Clin Pharmacol. 1981;21(3):229–233. doi: 10.1007/BF00627925. [DOI] [PubMed] [Google Scholar]
  10. Ochs H. R., Greenblatt D. J., Arendt R. M., Hübbel W., Shader R. I. Pharmacokinetic noninteraction of triazolam and ethanol. J Clin Psychopharmacol. 1984 Apr;4(2):106–107. doi: 10.1097/00004714-198404020-00010. [DOI] [PubMed] [Google Scholar]
  11. Ochs H. R., Greenblatt D. J., Knüchel M. Differential effect of isoniazid on triazolam oxidation and oxazepam conjugation. Br J Clin Pharmacol. 1983 Dec;16(6):743–746. doi: 10.1111/j.1365-2125.1983.tb02256.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Ochs H. R., Greenblatt D. J., Knüchel M. Kinetics of diazepam, midazolam, and lorazepam in cigarette smokers. Chest. 1985 Feb;87(2):223–226. doi: 10.1378/chest.87.2.223. [DOI] [PubMed] [Google Scholar]
  13. Ochs H. R., Greenblatt D. J., Locniskar A., Weinbrenner J. Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. Klin Wochenschr. 1986 Dec 1;64(23):1217–1221. doi: 10.1007/BF01734459. [DOI] [PubMed] [Google Scholar]
  14. Ochs H. R., Greenblatt D. J., Otten H. Disposition of oxazepam in relation to age, sex, and cigarette smoking. Klin Wochenschr. 1981 Aug 17;59(16):899–903. doi: 10.1007/BF01721923. [DOI] [PubMed] [Google Scholar]
  15. Pakes G. E., Brogden R. N., Heel R. C., Speight T. M., Avery G. S. Triazolam: a review of its pharmacological properties and therapeutic efficacy in patients with insomnia. Drugs. 1981 Aug;22(2):81–110. doi: 10.2165/00003495-198122020-00001. [DOI] [PubMed] [Google Scholar]
  16. Roth T., Roehrs T. A., Zorick F. J. Pharmacology and hypnotic efficacy of triazolam. Pharmacotherapy. 1983 May-Jun;3(3):137–148. doi: 10.1002/j.1875-9114.1983.tb03237.x. [DOI] [PubMed] [Google Scholar]
  17. Salmons P., Sims A. Smoking profiles of patients admitted for neurosis. Br J Psychiatry. 1981 Jul;139:43–46. doi: 10.1192/bjp.139.1.43. [DOI] [PubMed] [Google Scholar]
  18. Scavone J. M., Greenblatt D. J., Friedman H., Shader R. I. Enhanced bioavailability of triazolam following sublingual versus oral administration. J Clin Pharmacol. 1986 Mar;26(3):208–210. doi: 10.1002/j.1552-4604.1986.tb02935.x. [DOI] [PubMed] [Google Scholar]
  19. Smith R. B., Divoll M., Gillespie W. R., Greenblatt D. J. Effect of subject age and gender on the pharmacokinetics of oral triazolam and temazepam. J Clin Psychopharmacol. 1983 Jun;3(3):172–176. [PubMed] [Google Scholar]
  20. Smith R. B., Gwilt P. R., Wright C. E., 3rd Single- and multiple-dose pharmacokinetics of oral alprazolam in healthy smoking and nonsmoking men. Clin Pharm. 1983 Mar-Apr;2(2):139–143. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES